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Abstract
Cystic fibrosis (CF) is the most common genetic disease in Caucasians that 
increases the mortality rate. This disease retards the passage of water and salt 
through the cells and therefore affects the vital functions of different organs. 
Pulmonary cystic fibrosis is the most common and responsible for the majority of 
symptoms, burden of care, and mortality. The gene that causes the disease has now 
been identified and sequenced. The lung diseases with CF are usually have three 
pathological elements; mucus obstruction, inflammation, and infection. In the last 
century, the relationship between CF, respiratory microbiology, and inflammation 
has been understood with increased longevity and development of new treatments 
and laboratory techniques. In this chapter, we will illustrate causes of CF lung 
diseases and modern therapeutic strategies.
Keywords: cystic fibrosis, pathogenic bacteria, pneumonia infection, pulmonary 
inflammation, treatment guidelines
1. Introduction
Cystic fibrosis (CF) arises due to recessive mutations in the CF transmembrane 
regulator (CFTR) gene. This genetic disorder is carried out when two carrier parents 
transport the mutant CFTR gene to their child. Although no symptoms appear in 
the carriers, CF can be detected by genetic testing. CF-pulmonary diseases are usu-
ally associated with three pathological aspects; airway obstruction, infection, and 
inflammation. According to previous studies, children are most frequently infected 
by this disease with high rate of mortality. Staphylococcus aureus is the main cause of 
bronchitis, bronchiectasis, and pulmonary abscesses arising in the bronchi, which 
are usually accompanied by tenacious greenish-gray mucopurulent material [1, 2].
The mutation that attacks CFTR gene leads to CF, and obstruction in the air-
ways with abnormal mucus, infection, and inflammation is present. Although the 
current treatments cannot halt the disease progression, good nutrition, defective 
mucus clearance, and treatment of inflammation and infection greatly improve CF 
of the respiratory system and its complications [3]. There is a controversial relation-
ship between infection and inflammation. Some scientists think that the infection 
should precede the inflammation of airways, while others suggest the opposite [4].
Americans and Europeans are more susceptible to CF. One in 29 people of 
Caucasian ancestry is a healthy carrier of the CF gene mutation [5]. Detection of CF 
in early phases is very useful due to symptom reduction, health improvement, and 
low cost. For example, since 2010s, all American newborns undergo screening for 
CF to provide a chance for recovery if the disease is diagnosed. Most patients of CF 
must take pancreatic enzymes to digest food effectively, and some require insulin 
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for diabetes mellitus. The treatment cost of CF is very high because the drugs which 
treat and prevent the pulmonary diseases are very expensive [6]. Walaa et al. [7] 
report that 60 Egyptian children are affected by CF (6 months to 14 years). Salty 
skin is the most common symptom in the children affected with CF, because they 
suffer from dehydration due to loss of exuberant salty sweat. The percentage of 
ill males is 63%, while the percentage of ill females is 37%. Positive consanguinity 
of patients is 57%. 23% of patients has a positive family history of CF; the most 
frequent clinical presentation is pulmonary disease (84%), followed by pancreatic 
insufficiency (56%). The scientific material of this chapter aims to clearly interpret 
the roles of infection and inflammation in CF lung disease pathogenesis. Also, we 
will shed light on the therapeutic approaches to both infection and inflammation.
2. Microbes: CF interaction
2.1 Microbiology of CF lung disease
Severe and uncontrolled microbial infection may lead to CF. Microbes usually 
invade the airway luminal mucus, rather than tissues. Although Staphylococcus 
aureus is the main pathogenic agent for CF, many other bacteria are recorded with 
the development of both treatments and laboratory methods. The detection of 
pathogenic bacteria of CF depends on the cultivation of respiratory samples (e.g., 
sputum, bronchoalveolar lavage fluid, oropharyngeal swabs, or sinus samples) 
on the nutritive and selective media. Moreover, there are advanced techniques by 
which CF microbes are identified. Current methods mainly depend on cultivation 
of pathogenic bacteria on synthetic microbiological growth media and follow the 
incubation conditions to allow good growth and culture characteristics of patho-
gens [8]. Conventional techniques including microscopic and biochemical investi-
gations revealed that the pathogenic microbes infecting CF airways usually exist in 
biofilms, which provide complete defense mechanism to the pathogens [9, 10].
2.2 CF respiratory pathogens
2.2.1 Staphylococcus aureus
Staphylococcus aureus is a Gram-positive bacterium and is the first CF respira-
tory pathogen. Children are more susceptible to CF lung diseases than adults, 
and they are usually affected by S. aureus, which has been associated with higher 
airway inflammation [11, 12] and lung dysfunctions [13, 14]. This infection can 
be lethal when associated with Pseudomonas aeruginosa [15]. This association may 
lead to worse outcomes, if P. aeruginosa is associated with specific subtypes of S. 
aureus such as methicillin-resistant S. aureus (MRSA) and small-colony variants of 
S. aureus (SCVs). S. aureus infection in adults is harmless than in children, because 
lung functions are better [16] and there are lower complications [17]. Accordingly, 
the pathogenicity of S. aureus has two levels: the first is high when the infection 
occurs in children or in the absence of P. aeruginosa, and the second is very high 
(extreme) when the host is infected by specific subtypes of S. aureus (such as MRSA 
or SCVs). On the other hand, S. aureus may be nonpathogenic, but just serves as a 
marker of early or mild disease as with children and adults, respectively [18].
The two subtypes of S. aureus which are mentioned above (MRSA and SCVs) 
as well as oxacillin-resistant S. aureus (ORSA) are usually identified either by their 
resistance to these β-lactams or by carriage of the mecA gene, which encodes this resis-
tance. The subtypes of S. aureus SCVs are slow-growing, antibiotic-resistant variants 
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that are difficult to detect with conventional cultures and require special laboratory 
methods. SCVs are associated with decreasing lung functions, and they may be treated 
with antibiotics including aminoglycosides and sulfonamides [19]. MRSA are tightly 
accompanied with CF lung disease especially in the last 20 years. A lot of people are 
infected with MRSA due to hospitalization and worse use of antibiotics [20–22]. Many 
studies reported that MRSA are associated with CF lung disease in particular decrease 
of lung functions [23]. Moreover, MRSA is an independent risk factor for decreasing 
lung functions and respiratory exacerbations [24] and for increased mortality [25]. 
There are some similarities between the two subtypes (MRSA and SCVs): antibiotic 
treatment, antibiotic resistance, and higher lung disease severity.
In some countries where CF lung disease is spreading, anti-staphylococcal 
agent is provided as a prophylaxis approach during childhood particularly when P. 
aeruginosa is detected early [26]. Many of antibiotics are used to eradicate S. aureus 
and P. aeruginosa as co-infectious agents of CF lung disease, but the most commonly 
used antibiotics are aminoglycosides and sulfonamides [27].
2.2.2 Pseudomonas aeruginosa
After overcoming S. aureus by effective anti-staphylococcal agents, P. aeruginosa 
became the most common and important pathogen related to CF-pulmonary diseases 
[28]. P. aeruginosa infection is associated with decreasing lung functions, severe 
inflammation of the respiratory tract, a greater risk of respiratory exacerbations, and 
high rate of mortality [29]. Early detection of P. aeruginosa is a helpful factor for full 
eradication, while chronic infection cannot be eradicated. Also, eradication of P. aeru-
ginosa can be carried out by using antipseudomonal bioagents [30]. In contrast with 
S. aureus infection, P. aeruginosa infection is higher in adults than in children. At the 
end-stage of CF-pulmonary disease, P. aeruginosa is only present as a main pathogen 
for respiratory tract 31].
Despite P. aeruginosa usually producing numerous toxins as virulence factors, 
it may loss these virulence factors or their regulatory genes during chronic CF 
infections [32]. After invasion of lungs with P. aeruginosa, the mucoid colonies are 
formed due to exuberant production of alginate as one of the phenotypic changes 
due to chronic infection of CF-pulmonary disease [33]. The mucoid texture pro-
vides high rates of persistence and resistance for many antimicrobial agents as 
well as full adaptation to the respiratory airways. P. aeruginosa may be epidemic or 
non-epidemic, but the former is associated with worse outcomes such as high rate 
of mortality and requirement for lung transplantation [34].
Although P. aeruginosa is a multidrug resistant pathogen and usually leads to 
severe pulmonary CF, it leads to worse outcomes when associated with MRSA 
and SCVs. Prophylaxis by using of antibiotics is not recommended in the recent 
approach of P. aeruginosa treatment due to severe adverse events of antibiotics, but 
if P. aeruginosa is early detected, the treatment course with antibiotics must begin 
for complete eradication and to decrease the risk of exacerbations. Recently, inhaled 
antibiotics such as tobramycin and aztreonam are sufficient for eradication without 
any additional oral antibiotics such as ciprofloxacin [35]. Although inhaled antibi-
otics are sufficient for P. aeruginosa treatment without oral antibiotics, the clinical 
reports are revealing that, the combination between two classes of antibiotics leads 
to longer periods of clinical stability than does a single class [36].
2.2.3 Burkholderia cepacia complex
Burkholderia cepacia complex (BCC) is a group of Gram-negative bacteria and 
is comprised of at least 18 species. Of these, two species are the most common and 
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associated with CF lung infections and disease, B. cenocepacia and B. multivorans, but 
the latter is more distributed than the former. Nevertheless, B. cenocepacia is associated 
with more rapid lung function decline and mortality rate than B. multivorans. Other 
BCC species are less common, and their clinical associations are less well defined such 
as B. gladioli [37]. Burkholderia CF infections are notorious because they are associated 
with more severe lung disease, they are transmissible among persons with CF, they are 
resistant to multi-antibiotics, and epidemic strains can infect CF patients after internal 
contact at camps and clinics [38]. Associated outcomes often range from clinical quies-
cence to rapidly progressive, necrotizing pneumonia and fatal septic disease “cepacia 
syndrome” [39]. Therapy is usually limited to specific antibiotics as needed [40, 41].
2.2.4 Stenotrophomonas maltophilia
Stenotrophomonas maltophilia is a Gram-negative bacterium, which is widely 
spreading in the United States in recent years as CF pathogen especially among 
adolescents and young adults. This bacterium has intrinsic and acquired resistance 
to many antibiotics. No clear evidence for treatment of this pathogen so far [42].
2.2.5 Haemophilus influenzae
Haemophilus influenzae is a Gram-negative bacterium and is firstly detected in CF 
respiratory cultures. This bacterium is more prevalent in children and less common in 
adults. Although its association with CF complications is controversial, it is associated 
with non-CF bronchiectasis and chronic obstructive pulmonary disease. The cultiva-
tion of this bacterium is difficult and usually requires specific conditions for detection. 
The recent isolates of H. influenzae are non-typeable and unencapsulated since the vac-
cine of H. influenzae type B (HIB) has been discovered. This bacterium is well known 
as resistant to β-lactam antibiotics due to its production of β-lactamase; therefore, 
treatments usually include a β-lactamase inhibitor such as amoxicillin-clavulanate [43].
2.2.6 Achromobacter xylosoxidans
Achromobacter xylosoxidans is a Gram-negative bacterium that is similar to P. 
aeruginosa. Although this bacterium is widely spreading in the United States, it 
remains low in CF lung diseases (<10%). This bacterium is associated with worse 
radiographic and spirometric measures of lung disease. Similar to P. aeruginosa and 
BCC, A. xylosoxidans is the dominant, and occasionally, bacterium is isolated from 
CF patients at end-stage. Some microbes are notorious due to their resistance to 
many antibiotics, so their treatment is limited [44].
2.2.7 Nontuberculous mycobacteria
Nontuberculous mycobacteria represent 6–30% of CF prevalence. Two groups 
of mycobacteria, accounting for six species, are currently considered important CF 
pathogens: Mycobacterium avium and Mycobacterium abscessus complexes. The treat-
ment of nontuberculous mycobacteria has two phases: multiple intravenous antibiotics 
for weeks to months or multiple inhaled and oral antibiotics for months to years. 
Side-effects and toxicities are common and can be troublesome [45].
2.2.8 Fungi and viruses
A lot of fungi are isolated from CF patients, including yeasts such as Candida spp. 
and filamentous fungi such as Aspergillus spp. There is a respiratory disease known as 
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allergic bronchopulmonary aspergillosis (ABPA), in which the bronchia are affected 
by inflammation due to Aspergillus infection. Patients of CF and other chronic airway 
diseases can develop an IgE-mediated allergic airway disease known as ABPA. The 
treatment for which primarily involves steroids, although the addition of an antifun-
gal such as itraconazole may allow for lower doses of steroids. Human respiratory 
viruses are not thought to chronically infect the CF airway, but they have been shown 
both to be important and common triggers of CF respiratory exacerbations [45].
2.3 CF airway microbiome
Many studies which are concerned with identification of the microbiota of the 
respiratory system depend on DNA-sequencing techniques. The results of these 
techniques revealed that there is a wide diversity of microbiota inhabiting the 
respiratory system. This diversity of microbiota is high in young CF patients who 
have better lung functions and subsequently need fewer courses of antibiotics and 
vice versa in the case of adults. The most dominant microbiota in infected lungs of 
CF patients are P. aeruginosa, BCC, and A. xylosoxidans [46].
3. Immune response in CF lung disease
Destruction of the respiratory airways may carry out due to the chronic CF 
infections. This damage is mediated by abnormal response of the host to airway 
infections, which in turn leads to irreversible bronchiectasis and lung function 
decline [47]. Many studies report that, bacterial infection and inflammation are 
leading to triggering of neutrophils [48]. Moreover, the dysfunction of CF-CFTR is 
a main cause of altered immune defense and disorders in the airway’s environment. 
Appearance of neutrophil elastase (NE) is a good biomarker of disease [49].
The mutant CFTR gene leads to production of an abnormal protein, resulting in 
abnormal transport of salt and water across lining cells of the respiratory system, 
digestive system, and genital tracts. Insufficient water transport to the lining cells 
of the airways leads to formation of more thick and viscous respiratory secretions 
which clog small airways. Due to water reduction, the mucus becomes stagnant and 
infected with bacteria such as P. aeruginosa that may be inhaled or brought into the 
lungs through the mouth. Due to stagnant mucus, infection and chronic inflamma-
tion are developed. The tenacity of stagnant mucus is increased because the inflam-
matory cells are trapped in it. Due to accumulation of stagnant and infected mucus 
inside the airways, the bronchi dilate, and subsequently their walls are weakened. 
This phenomenon is called bronchiectasis that results in further airflow obstruc-
tion. According to the previous case, the respiratory cycle can be called the viscous 
cycle in which airway obstruction, inflammation, and infection are present, which 
lead to decrease of lung functions, respiratory failure, and death. Decrease of lung 
functions especially in children can also be due to exposure to smoking and polluted 
air, which also leads to pulmonary exacerbations.
The defective CF gene leads to defective CFTR and thick viscous secretions, 
which in turn lead to bronchial obstruction then to an infection then inflammation 
and finally bronchiectasis. Infection, inflammation, and bronchiectasis can lead 
to bronchial obstruction (Figure 1). Infection amplifies defective CF gene, which 
in turn leads to defective CFTR, which activates the resident airway inflammatory 
cells, which stimulate neutrophils and neutrophil products such as neutrophil 
elastase and monocytes, and finally bronchiectasis occurs (Figure 2).
The surface of epithelial lining cells of respiratory airways is dehydrated and 
acidified due to CFTR dysfunction, and abnormal mucociliary clearance is carried 
Cystic Fibrosis - Facts, Management and Advances
6
out. Dehydration is carried out due to water loss, while acidification is carried out 
due to bicarbonate loss [50, 51]. The neutrophilic inflammatory response is higher 
in CF than in non-CF patients. However, the neutrophilic inflammatory response is 
reduced in neutrophil apoptosis. Neutrophils and their products are accumulated due 
to deficiency in mucociliary clearance and macrophage dysfunction [52]. The passage 
airways may destruct by the action of anti-proteases, such as alpha-1-antitrypsin, a 
serine protease inhibitor, and secretory leukocyte protease inhibitor. So, neutrophil 
Figure 2. 




products such as proteases and elastases are released to react with anti-proteases and 
therefore avoid their deleterious action toward the passage airways [53, 54].
Some substances act as mediators of immune response and serve as important 
biomarkers of disease progression, such as neutrophil elastase, which is abundant 
in induced sputum in children with CF compared to control children [55]. High 
level of neutrophil elastase in induced sputum indicates lung dysfunctions and 
bronchiectasis [13]. The inflammation of the passage airways in sputum is reduced 
after detection and using of effective antibiotics for treatment of a CF-pulmonary 
diseases [56]. Inflammatory proteins are considered potential biomarkers of disease 
in CF. For example, the blood plasma proteins are biomarkers of CF disease [57].
The common example of immune response in CF lung disease is the immune 
response to P. aeruginosa [58]. CFTR dysfunction predisposes the host to infection 
with P. aeruginosa and then allows for chronic infection and subsequent reduced 
opportunity for eradication. Moreover, P. aeruginosa interacts with other bacterial 
pathogens including S. aureus and B. cepacia complex to alter the inflammatory 
response [59].
4. Anti-inflammatory therapy of CF
4.1 Ibuprofen
Ibuprofen inhibits neutrophil migration and aggregation [60]. It improves the 
lung functions especially in patients younger than 13 years. Gastrointestinal bleed-
ing may be associated with chronic therapy. Recent studies report that high-dose 
ibuprofen could slow the progression of lung disease in CF, particularly in children 
with mild disease [61]. Despite the efficacy of ibuprofen for CF lung disease 
therapy, its use is uncommon compared to other CF therapies due to severe adverse 
effects such as kidney failure and gastric bleeding [62].
4.2 Azithromycin
Azithromycin is a broad-spectrum antibiotic belonging to macrolide group, and 
at the same time, it has immunomodulatory effects, so it has high effectiveness in 
the treatment of CF lung disease and other chronic inflammatory conditions [63]. 
Azithromycin may be used for a very long period (chronic azithromycin) either with 
or without chronic P. aeruginosa infection [64]. With chronic P. aeruginosa infection, 
azithromycin is taken thrice weekly for 6 months to improve forced expiratory volume 
(FEV) and subsequently decrease the risk of pulmonary exacerbations. On the other 
hand, without chronic P. aeruginosa infection, azithromycin could reduce 50% of pul-
monary exacerbations and improve weight, but without improvement of lung func-
tions [65]. Azithromycin is recommended for CF treatment in patients suffering from 
chronic P. aeruginosa infection and those without chronic infection aged 6 years and 
older [66]. Despite the high durability of azithromycin, resistant bacteria are emerging, 
so the treatment should be reassessed every 6–12 months. Azithromycin is prohibited 
for patients with nontuberculous mycobacteria (NTM) unless it is prescribed in 
combination with other anti-mycobacterial medications as part of NTM therapy.
4.3 Corticosteroids and leukotriene receptor antagonists
Corticosteroids, especially its systemic forms, or cortisones are powerful 
anti-inflammatory agents which are widely used in the treatment of CF. Although 
systemic corticosteroids can intensively improve lung functions, they have adverse 
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effects that outweigh any benefit [67]. Inhaled corticosteroids do not have any 
efficacy in the treatment of CF [68]. Therefore, the treatment of CF by systemic or 
inhaled corticosteroids is not recommended by the Cystic Fibrosis (CF) Foundation 
[66]. On the other hand, leukotriene receptor antagonists (LTRAs) are nonsteroidal 
oral medications, which are used as anti-inflammatory bronchoconstriction pre-
ventors. LTRAs block a chemical reaction that leads to inflammation in the airways. 
LTRAs are effective as antihistamines, and they are better than placebo, but less 
effective than nasal corticosteroids in improving symptoms and quality of life in 
patients with seasonal allergic rhinitis [69].
5. Treatment management of CF
CF carrier testing is recommended for everybody especially for Caucasian 
women whether they are considering pregnancy or already pregnant. CF-carrier 
test must be made before marriage, because the marriage of the positive CF-carriers 
leads offspring affected with CF, and vice versa. So, the early diagnosis of CF either 
before birth or for newborns allows for earlier and faster treatment in CF centers 
and avoidance of serious complications including poor growth. CF centers must 
be accredited by the CF Foundation. CF centers have multidisciplinary teams of 
physicians, nurses, respiratory therapists, dietitians, and social workers who can 
care for both adult and pediatric patients [70]. Good nutrition for affected persons 
with CF increases lung functions and life expectancy. Once CF disease is diagnosed, 
the patient must follow a nutrition program that is including a high-calorie diet, 
pancreatic enzymes and a liberal-fat. Essential vitamins must be supplemented to 
reduce the risk of deficiency of certain fat-soluble vitamins.
Although ill infants and young children with CF have intermittent cough and 
wheezing, structural and functional abnormalities in the lung as early as the first 
few months of life are detected. CF treatments include physical methods to elimi-
nate thick secretions from the chest. CF treatments with chemical methods include 
prescription of different medications, such as dornase alfa and hypertonic saline 
as thinners of sticky airway secretions, albuterol as bronchodilator, tobramycin as 
inhaled antibiotic, and ibuprofen and azithromycin as anti-inflammatory drugs 
[71]. Preventive measures against CF or its complications necessarily require 
frequent follow-up for nutrition, lung functions, and screening for complications in 
an accredited CF center.
6. Conclusion
CF lung disease is one of the many causes of morbidity and mortality world-
wide. CF lung disease has indefinite symptoms including airway obstruction, infec-
tion, and inflammation. This disease is associated with different microorganisms 
such as P. aeruginosa, S. aureus, and B. cepacia complex. Several medications are 
used as antimicrobial treatment for these pathogens. The airway microbiota is influ-
enced by several factors including the environment, host, disease progression, and 
antibiotic treatment. Immune response to microbes in the CF airways is high due to 
dysfunction of CFTR protein. Although the recent therapies for airway infections 
and immune-inflammatory response are effective, they cannot fully stop disease 
progression. Today, CF lung disease has less risk because anti-inflammatory and 
antimicrobial therapies are in continuous development. Eventually, the authors rec-
ommend that, CF-carrier test must be made in particular before the marriage, early 
treatment of respiratory diseases especially if CF disease is diagnosed, avoidance of 
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relatives marriage because it enhances an emergence of genetic diseases including 
CF, and finally, the treatment with corticosteroids (cortisone) must be under full 
control by a physician due to its severe adverse effects.
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